OS Therapies (NYSE:OSTX - Get Free Report) had its price target lifted by research analysts at Maxim Group from $8.00 to $15.00 in a report issued on Thursday,Benzinga reports. The brokerage currently has a "buy" rating on the stock. Maxim Group's target price indicates a potential upside of 408.47% from the company's previous close.
Separately, D. Boral Capital reissued a "buy" rating and set a $20.00 price objective on shares of OS Therapies in a report on Wednesday.
Read Our Latest Report on OS Therapies
OS Therapies Trading Down 28.4 %
Shares of OS Therapies stock traded down $1.17 on Thursday, hitting $2.95. 1,628,859 shares of the company's stock traded hands, compared to its average volume of 1,970,632. The business's 50-day simple moving average is $3.32. OS Therapies has a 52-week low of $1.58 and a 52-week high of $7.00.
Insiders Place Their Bets
In other news, major shareholder Shalom Auerbach sold 16,720 shares of the business's stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $6.74, for a total value of $112,692.80. Following the completion of the sale, the insider now directly owns 2,531,211 shares in the company, valued at approximately $17,060,362.14. The trade was a 0.66 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Hedge Funds Weigh In On OS Therapies
A hedge fund recently bought a new stake in OS Therapies stock. Virtu Financial LLC purchased a new position in OS Therapies Inc (NYSE:OSTX - Free Report) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 10,045 shares of the company's stock, valued at approximately $28,000.
About OS Therapies
(
Get Free Report)
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.
Further Reading
Before you consider OS Therapies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OS Therapies wasn't on the list.
While OS Therapies currently has a "Strong Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for February 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
